SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10889)7/23/1999 12:36:00 AM
From: LarryS  Read Replies (1) | Respond to of 17367
 
Maybe a good buy would be to wait until
we get a better understanding (after unblinding)
of how effective Neuprex is. If it's as good as we
hope buy AGN then, because virtually none of their
investors/analysts will know anything about BPI/Iprex/Xoma. When the word gets around, and their investors see value in Iprex, the stock might make a
move up.

Speaking of analysts, maybe some that follow AGN
will do some research on Iprex and be intrigued
by Xoma...and issue buys.

Hope tomorrow will move us back above 7. Earnings
and unblinding in less than a month...sure is starting
to get interesting after all these months.



To: aknahow who wrote (10889)7/23/1999 1:05:00 AM
From: Bluegreen  Read Replies (1) | Respond to of 17367
 
George, institutions usually don't hide SOC in their realm if it is far superior to other regions. As a matter of fact they can't wait to shout it out before someone else stumbles on the improvement and claims it as their institution's idea. I would think St. Mary's in west London has its problems with G 8s and above just like everyone else.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News